Myeloid growth factors clinical practice guidelines in oncology

Jeffrey Crawford, Betsy Althaus, James Armitage, Douglas W. Blayney, Spero Cataland, David C. Dale, George D. Demetri, James Foran, Mark L. Heaney, Sally Htoy, Dwight D. Kloth, Gary H. Lyman, Laura Michaud, Susannah Motl, Saroj Vadhan-Raj, Michael K. Wong

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


Chemotherapy-induced neutropenia is the major dose-limiting toxicity of systemic cancer chemotherapy, associated with substantial morbidity, mortality, and cost. Although prophylactic colony-stimulating factors (CSFs), can reduce this complication, their routine use in all patients on myelosuppressive chemotherapy is prohibitively costly. Selective use in patients most at risk for neutropenia may enhance cost-effectiveness, but determining the actual risk is complicated by issues in reporting myelosuppression and dose intensity, among other factors. For this reason, NCCN experts developed these guidelines to assist practitioners in the appropriate prophylactic use of CSFs.

Original languageEnglish (US)
Pages (from-to)540-555
Number of pages16
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number4
StatePublished - Jul 2005


  • Chemotherapy
  • Colony-stimulating factors
  • Fever
  • Morbidity
  • Myeloid growth factors
  • NCCN Clinical Practice Guidelines
  • Neutropenia
  • Toxicity

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Myeloid growth factors clinical practice guidelines in oncology'. Together they form a unique fingerprint.

Cite this